These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 21720990)

  • 21. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study.
    Potosky AL; Davis WW; Hoffman RM; Stanford JL; Stephenson RA; Penson DF; Harlan LC
    J Natl Cancer Inst; 2004 Sep; 96(18):1358-67. PubMed ID: 15367568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome of adjuvant radiotherapy after radical prostatectomy for prostate cancer patients.
    Suzuki K; Nakano K; Morita T
    Urol Int; 2010; 84(4):382-7. PubMed ID: 20224263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
    Palma D; Tyldesley S; Pickles T;
    Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Major 30-day complications after radical radiotherapy: a population-based analysis and comparison with surgery.
    Alibhai SM; Leach M; Warde P
    Cancer; 2009 Jan; 115(2):293-302. PubMed ID: 19025976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
    Tsai HK; Chen MH; McLeod DG; Carroll PR; Richie JP; D'Amico AV
    Cancer; 2006 Dec; 107(11):2597-603. PubMed ID: 17039498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radical prostatectomy for clinical T4 prostate cancer.
    Johnstone PA; Ward KC; Goodman M; Assikis V; Petros JA
    Cancer; 2006 Jun; 106(12):2603-9. PubMed ID: 16700037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
    D'Amico AV; Whittington R; Malkowicz SB; Cote K; Loffredo M; Schultz D; Chen MH; Tomaszewski JE; Renshaw AA; Wein A; Richie JP
    Cancer; 2002 Jul; 95(2):281-6. PubMed ID: 12124827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of postprostatectomy external beam radiotherapy on quality of life: results from the Cancer of the Prostate Strategic Urologic Research Endeavor.
    Hu JC; Elkin EP; Krupski TL; Gore J; Litwin MS
    Cancer; 2006 Jul; 107(2):281-8. PubMed ID: 16779794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10).
    Konski A; Sherman E; Krahn M; Bremner K; Beck JR; Watkins-Bruner D; Pilepich M
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):788-94. PubMed ID: 16109464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness of Primary Radiation Therapy Versus Radical Prostatectomy for Intermediate- to High-Risk Prostate Cancer.
    Dorth JA; Lee WR; Chino J; Abouassaly R; Ellis RJ; Myers ER
    Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):383-390. PubMed ID: 29353655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. External beam radiotherapy for prostate cancer.
    Pinkawa M
    Panminerva Med; 2010 Sep; 52(3):195-207. PubMed ID: 21045776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy.
    King CR; Spiotto MT
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):23-7. PubMed ID: 18207668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients.
    Ost P; Fonteyne V; Villeirs G; Lumen N; Oosterlinck W; De Meerleer G
    Eur Urol; 2009 Oct; 56(4):669-75. PubMed ID: 19501453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postprostatectomy adjuvant versus salvage radiotherapy: a complication-adjusted number-needed-to-treat analysis.
    Jani AB; Kao J
    Cancer; 2005 May; 103(9):1833-42. PubMed ID: 15756656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduction of irradiation volume and toxicities with 3-D radiotherapy planning over conventional radiotherapy for prostate cancer treated with long-term hormonal therapy.
    Yamazaki H; Nishiyama K; Tanaka E; Maeda O; Meguro N; Kinouchi T; Usami M; Kakimoto K; Ono Y; Nishimura T
    Anticancer Res; 2008; 28(6B):3913-20. PubMed ID: 19192649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low pre-radiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer.
    Sasaki T; Nakamura K; Shioyama Y; Ohga S; Toba T; Urashima Y; Yoshitake T; Terashima H; Koga H; Naito S; Noma H; Komatsu K; Yamaguchi A; Hiratsuka Y; Hirano T; Hanada K; Abe M; Fujisawa Y; Honda H
    Anticancer Res; 2006; 26(3B):2367-74. PubMed ID: 16821618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer.
    Konski A; Watkins-Bruner D; Feigenberg S; Hanlon A; Kulkarni S; Beck JR; Horwitz EM; Pollack A
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):408-15. PubMed ID: 16887291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer.
    Ost P; De Troyer B; Fonteyne V; Oosterlinck W; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1316-22. PubMed ID: 20675081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.